Targeted Treatment Trastuzumab is found to greatly Improve Long Term Survival of HER2 Breast Cancer Patients | ||
| Egyptian Journal of Medical Research | ||
| Article 4, Volume 1, Issue 1, January 2020, Pages 43-54 PDF (257.82 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ejmr.2020.89043 | ||
| Authors | ||
| Mamdouh EL Sherbiny Ramadan; Mohamed Aly El-Wakil; Shahera Mohamed Gamal Shaaban* | ||
| Clinical Oncology Department, Faculty of Medicine, Beni-Suef University, Egypt | ||
| Abstract | ||
| The goal of this study is to assess the importance of adding adjuvant TRASTUZUMAB as a standard in her2 overexpressed breast cancer. Fifty female patients have known to be HER2 overexpressed breast cancer, recruited from the clinical oncology clinic at Beni-Suef University Hospital, and from the insurance hospital at Beni-Suef city. This is a retrospective study. This study was done within six months. The results of this trial indicate that one year of adjuvant trastuzumab should be considered a standard on completion of locoregional therapy and neoadjuvant or adjuvant chemotherapy. That study indicated that adding trastuzumab to chemotherapy had improved overall survival &disease free survival, all the recruited patients in that study were still alive till the end of the study and about 8% (n=4) vs 92% (n=46) of patients developed distant recurrences. Receiving adjuvant TRASTUZUMAB for 1year without delaying in initiation (≤ 6 months) after diagnosis, offers dramatic effects on overall survival OS and disease free survival DFS. | ||
| Keywords | ||
| Disease-free survival (DFS); overall survival (OS); Neoadjuvant chemotherapy | ||
|
Statistics Article View: 348 PDF Download: 392 |
||
